

## Accepted Manuscript

Review

Preclinical Models of Nonalcoholic Fatty Liver Disease

Prasanna K. Santhekadur, Divya P. Kumar, Arun J. Sanyal

PII: S0168-8278(17)32422-4

DOI: <https://doi.org/10.1016/j.jhep.2017.10.031>

Reference: JHEPAT 6741

To appear in: *Journal of Hepatology*

Received Date: 19 October 2017

Revised Date: 29 October 2017

Accepted Date: 31 October 2017

Please cite this article as: Santhekadur, P.K., Kumar, D.P., Sanyal, A.J., Preclinical Models of Nonalcoholic Fatty Liver Disease, *Journal of Hepatology* (2017), doi: <https://doi.org/10.1016/j.jhep.2017.10.031>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**PRECLINICAL MODELS OF NONALCOHOLIC FATTY LIVER DISEASE**

Prasanna K. Santhekadur PhD, Divya P. Kumar PhD and Arun J. Sanyal M.B.B.S, M.D.

**Running title:** animal models of NAFLD

**Keywords:** nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, NAFLD activity score, transcriptome, mouse models, preclinical models

Corresponding author: Arun J. Sanyal M.D.  
Title: Professor of Medicine, Physiology and Molecular Pathology  
Address: MCV Box 980341  
Richmond, VA 23298-0341  
Phone: (804) 828 6314  
Fax: (804) 828 2992  
Email: [arun.sanyal@vcuhealth.org](mailto:arun.sanyal@vcuhealth.org)

**Affiliation:**

1. Div. of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA.

**Grant support:**

- RO1 DK 105961
- T32 DK 07150

**Conflicts of Interest:**

P.K. Santhekadur: None to report

D.P. Kumar: None to report

A.J. Sanyal: None for this project. Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Janssen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Immuron, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Novo Nordisk, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UpToDate.

Download English Version:

<https://daneshyari.com/en/article/8729342>

Download Persian Version:

<https://daneshyari.com/article/8729342>

[Daneshyari.com](https://daneshyari.com)